October 3, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCTN TRIALS

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 472 1015 214% 765 543 985
ERLYTX 54 61 113% 46 7 61
GI 100 98 98% 74 -2 100
GU 256 281 110% 212 25 276
LEUK 354 755 213% 569 401 735
LUNG 817 553 68% 417 -264 555
LYMPH 181 368 202% 277 187 347
MELAN 364 0 0% 0 -364 0
MMYEL 192 108 56% 81 -84 102
MULT 25 44 175% 33 19 51
Total 2815 3283   2474 468 3212

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 3, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCORP TRIALS

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 578 206 35% 155 -372 186
PEOLC 52 27 51% 20 -25 67
PREV 169 0 0% 0 -169 0
SXQOL 958 607 63% 457 -351 589
Total 1757 840   632 -917 842

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 3, 2026 Page

CURRENT AND PROJECTED ACCRUAL

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG CTP TRIALS

BY STUDY

76% of Calendar Year is Past

Committee Study Projected
2026
Accrual		 2026
Accrual
to date		 Accrual
Last
12 Months
ERLYTX 21CTP.HN01 13 10 10
LEUK 21CTP.LEUK01 9 7 7
Total   22 17 17

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 3, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCTN TRIAL

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 352 689 195% 519 337 700
ERLYTX 42 45 106% 34 3 46
GI 157 129 82% 97 -28 125
GU 399 296 74% 223 -103 291
LEUK 182 344 189% 259 162 342
LUNG 551 356 64% 268 -195 355
LYMPH 173 292 168% 220 119 276
MELAN 228 8 3% 6 -220 8
MMYEL 135 68 50% 51 -67 63
MULT 14 19 135% 14 5 20
OTHER 57 64 111% 48 7 59
Total 2290 2310   1739 20 2285

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 3, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCORP TRIAL

BY COMMITTEE

76% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 534 163 30% 123 -371 155
GI 0 1 .% 1 1 1
PEOLC 37 24 64% 18 -13 54
PREV 341 226 66% 170 -115 229
SXQOL 665 499 75% 376 -166 482
Total 1577 913   688 -664 921

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 3, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCTN STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
BREAST III S2206: Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 10/30/2023 35 419 960 11.8 Jul-2030 6.7
    S2212: Breast, TNBC, Neoadj Chemo + Pembro 07/21/2023 38 1712 2400 70.8 Jul-2027 4.0
    S2511: Brst, de novo StgIV oligo, locoreg tx vs SOC 08/18/2026 1 0 534      
ERLYTX II SN2426: cSCC, IC Met/Inop, Amivantamab v Cetuximab 01/28/2026 8 11 86 1.7 Jul-2030 4.4
  II-III S2012: Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 12/02/2021 58 168 189 3.7 Mar-2027 5.2
  III S2505: Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 07/06/2026 2 0 296      
GI II S2104: Panc,Resect High-risk,Postop Adj Chemo vs Obs 10/14/2021 59 110 154 2.8 Jan-2028 6.2
  II-III S2303: Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 05/06/2024 28 121 224 5.2 May-2028 4.0
  III S2433: PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 12/26/2025 9 1 94 0.2 > 15 Yrs > 15 Yrs
GU II S2210: Pros, High Risk, BRCA, Neoadj Carbo 08/14/2023 37 6 44 0.0    
    S2427: Blad, MIBC, RT + Pembrolizumab 09/04/2025 12 51 111 7.2 Jun-2027 1.7
  III S1802: Pros, Stg IV, SST ± Surg/RT to Primary Tum 09/17/2018 96 1058 1273 8.2 Dec-2028 10.2
    S1931: RENAL, Stg IV, IO + Nephrectomy. vs IO Only 11/16/2020 70 162 336 2.2 Jun-2033 12.5
    S2312: Pros, MCRPC, Cab +/- Carb 09/03/2024 25 72 500 4.5 Sep-2034 10.0
    S2419: Renal, adv clear cell, IO +/- Biotx, BIOFRONT 04/22/2026 5 32 718 5.9 May-2036 10.0
LEUK II MM1OA-S03: AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 04/01/2025 18 29 102 3.5 Jun-2028 3.2
    MM1OA-S04: MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) 07/22/2026 2 1 126      
    MM1YA-S01: AML, High Risk, Age <60, 7+3 vs experimental 05/16/2024 28 91 335 4.0 Nov-2031 7.5
    S2507: ALL/ALAL, KMT2A-trans, Blina +/- Revumenib 09/22/2026 0 0 90      
  III S1925: CLL/SLL, Newly Dx HR, Early vs Delayed V+O 12/14/2020 69 209 247 4.8 May-2027 6.4
    S2504: Richter Trans., Untreated, R-CHOP +/- Pirto 06/01/2026 4 1 102 0.2 > 15 Yrs > 15 Yrs
  OTHER MYELOMATCH: MSRP for the NCI myeloMATCH Clinical Trials 05/16/2024 28 1333   52.8 .- . .
LUNG II S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 04/03/2023 42 28 44 0.5 Jun-2029 6.2
    S1900J: MET Amplification: Amivantamab Hyaluronidase 09/27/2024 24 4 88 0.0    
    S1900K: MET Exon 14: Tepotinib +/- Ramucirumab 12/18/2023 33 30 56 1.0 Dec-2028 5.0
    S1900N: AGAs: SG alone, I alone, or SG + I 08/03/2026 2 1 117      
    S2409: ESCLC, Durvalumab +/- Biomarker Directed Tx 09/08/2025 12 18 900 2.3 > 15 Yrs > 15 Yrs
  II-III S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab 04/28/2025 17 142 378 9.5 Oct-2028 3.4
  III S2414: NSCLC, Stg II-IIIB, Durva vs Surveillance 03/14/2025 18 14 306 1.0 > 15 Yrs > 15 Yrs
  OTHER LUNGMAP: NSCLC, Adv, Master 01/28/2019 92 4134   28.7 .- . .
LYMPH II S2114: NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 02/23/2023 43 253 396 8.8 Feb-2028 4.9
    S2207: LBCL, Transplant Inelig, Targeted Tx + Tafa 06/30/2023 39 42 173 0.5 > 15 Yrs > 15 Yrs
    S2506: NHL, R/R MZL, Mozun +/- Zanu or Pola 08/18/2026 1 0 138      
  III S2308: FL, LTB, Mosunetuzumab vs Rituximab 08/01/2024 26 431 600 23.2 May-2027 2.8
MMYEL II S2005: WM, Prev. Untreated, I/R or Z v V/R 06/24/2021 63 44 92 3.7 Nov-2027 6.4
  III S1803: MM, Maintenance, Len vs Len/Dara 06/27/2019 87 1338 1100 0.0    
    S2209: MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 05/30/2023 40 148 510 4.0 Apr-2034 10.8
    S2213: AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 12/01/2023 34 52 142 2.0 Jul-2030 6.6
MULT II S2101: Melan or HNSCC, Adv, Cabo + Nivo 10/14/2022 47 109 220 3.7 Apr-2029 6.5
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 3, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCORP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
CCD III S1703: Met Breast, STM-monitoring v Usual Care 07/16/2018 98 477 498 3.7 Mar-2027 8.6
    S2417CD: Colrec Surv, Follow-up w/ CTAC site 08/04/2025 13 132 654 13.0 Feb-2030 4.5
    S2424CD: A-PACT vs SOC for GOC communication 06/01/2026 4 5 1000 1.2 > 15 Yrs > 15 Yrs
PEOLC III S1501: Surv, Breast Stg IV, Card Tox w/ Carvedilol 09/15/2017 108 399 491 1.8 Dec-2030 13.2
    S2408: Panc Fistula Prevention, Lanreotide 02/14/2025   63 274      
SXQOL III S2205: ICE COMPRESS: Reduction of CIPN from Taxanes 03/16/2023 42 683 777 17.0 Mar-2027 4.0
  OTHER S2013: I-CHECKIT: ICI toxicity risk prediction study 08/16/2021 61 2658 3609 33.7 Feb-2029 7.5
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 3, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED CTP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
ERLYTX II 21CTP.HN01: HN, Recur/Met, Amivantamab + Chemo 03/05/2026 6 10 50 1.3 Apr-2029 3.1
LEUK II 21CTP.LEUK01: ALL, Ph+, Asciminib, Dasatinib and Prednisone 12/11/2025 9 7 55 1.2 Mar-2030 4.2
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.